ISSN: 0970-938X (Print) | 0976-1683 (Electronic)
An International Journal of Medical Sciences
Objective: To explore correlations between CD7, CD34, CD56 and HLA-DR expressions and its prognosis among patients with acute myeloid leukemia.
Methods: 225 patients with Acute Myeloid Leukemia (AML) with initial treatment and complete data in our hospital from Jan 2013 to Dec 2016 were selected as study objects. 30 healthy volunteers who took part in the marrow test but were not detected for leukemia in the same period were selected as control patients. Fresh bone marrow of all patients was abstracted, from which single cell was separated. Flow cytometer detection was given after using monoclonal antibody of living cells immunofluorescent. CD7, CD34, CD56 and HLA-DR expressions of bone marrow among patients were detected. Fluorescent antibody staining positive cells were equal or greater than 20%, they were positive; equal or greater than 50%, they were high expression. Various immunophenotypes distribution in AML patients with different types was given statistics. Complete Remission (CR) rate of different immunophenotype positive and negative patients were given statistics. Mean survival of different immunophenotype positive and negative patients were given statistics.
Results: There was no significant difference of leukemia patient and healthy volunteer in the aspects of age, sex, past medical history with relevant comparability (p>0.05). Antigen expression rate, from the high level to low were HLA-DR (58.22%), CD349 (50.67%), CD56 (30.67%), CD (723.11%). CR rate of patients in CD7, CD34, CD56 and HLA-DR positive groups were lower than negative group significantly, there were statistical differences between two groups (P<0.05). MST among patients in CD7, CD34, CD56 and HLA-DR positive group were lower than negative group significantly, there were statistical differences between two groups (P<0.01).
Conclusion: Complete remission rate of CD7, CD34, CD56 and HLA-DR antigen expression positive among patients with Acute Myeloid Leukemia (AML) is low, mean survival is short and prognosis is poor.Author(s): Shishan Xiao, Hongqian Zhu